Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

Eugene Braunwald 1,2*, Sara Saberi3, Theodore P. Abraham4, Perry M. Elliott5, and Iacopo Olivotto6

1Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women’s Hospital, 60 Fenwood Road, Boston, MA 02115, USA; 2Department of Medicine, Harvard Medical School, Boston, MA, USA; 3Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; 4UCSF HCM Center of Excellence, University of California San Francisco, San Francisco, CA, USA; 5Institute of Cardiovascular Science, University College London, London, UK; and 6Meyer Children’s Hospital, University of Florence, Florence, Italy

Received 6 April 2023; revised 9 August 2023; accepted 11 September 2023; online publish-ahead-of-print 7 October 2023

Graphical Abstract

The path to treatment of obstructive hypertrophic cardiomyopathy. (Top left) Haemodynamic observations demonstrated. Left ventricular (LV) obstruction and symptoms related to LV hypertrophy. (Bottom left) Discovery of genetic variants in ~40% of patients. (Centre) Sarcomeres in obstructive hypertrophic cardiomyopathy (oHCM) show excess of myosin–actin cross-bridges that are normalized by mavacamten. (Top right) Pre-clinical observations in mouse and pig models of oHCM. (Bottom right) The two placebo-controlled clinical trials of mavacamten in oHCM.
Hypertrophic cardiomyopathy (HCM) is a complex disorder that is caused by dysfunction of the cardiac sarcomere resulting in excessive cardiac myosin–actin cross-bridging and increased sensitivity to calcium. Core pathophysiologic features of HCM include left ventricular hypertrophy (LVH), most often involving the subaortic region of the inter-ventricular septum, microvascular ischaemia, myocardial fibrosis, and diastolic dysfunction. Sixty years ago, when the first detailed clinical reports of the disease were published, HCM was considered to be an uncommon condition with high mortality and limited treatment options. Today, it is estimated that 1.500 persons in the general population have a HCM phenotype. Hypertrophic cardiomyopathy is frequently inherited as an autosomal dominant trait with variable penetrance. Pathogenic variations most frequently occur in genes coding for the sarcomeric proteins beta myosin heavy chain 7 (MYH7) and myosin-binding protein C3 (MYBPC3). Pathogenic variants of myosin encoding genes alter the relaxed state of sarcomeric proteins causing increased cardiomyocyte contractility and energy requirements and impair left ventricular (LV) relaxation and filling. About 60% of all HCM patients have negative tests for sarcomeric variants, some of whom may present with a family history of the disease but may have a polygenic aetiology. Other patients are sporadic, without detectable genetic variants or a family history. The molecular basis for ventricular hypertrophy has not been established.

Approximately two-thirds of the patients with HCM have obstruction of the LV outflow tract (LVOT), a major determinant of symptoms and outcomes. The hyper-contractile phenotype, combined with septal hypertrophy and anatomical abnormalities of the mitral valve apparatus, leads to systolic anterior motion (SAM) of the mitral valve causing mitral-septal contact and subaortic obstruction, which is often dynamic and can be intensified with physiologic or pharmacologic interventions, such as exercise, the Valsalva manoeuvre, or a beta adrenergic agonist.

Hypertrophic cardiomyopathy has a diverse clinical presentation and course. Some patients may be asymptomatic or mildly symptomatic, while others experience severe symptoms that impact functional capacity. The most frequent symptoms are exertional dyspnoea, palpitations, fatigue, pre-syncope, and angina, the latter caused by myocardial ischaemia due to coronary arteriolar thickening and/or increased myocardial energy consumption. Significant complications include syncope, recurrent atrial fibrillation, ventricular tachycardia, stroke, heart failure, and sudden death. Implantable cardioverter defibrillator placement can reduce the risk of the latter in high-risk patients.

First-line treatment of obstructive HCM (oHCM) includes oral beta-blockers and/or non-dihydropyridine calcium channel blockers. Both drug classes slow heart rate, and their modest negative inotropic actions may provide some reduction of intra-cardiac obstruction. Disopyramide, an antiarrhythmic, may be added because of its additional negative inotropic action, but its anticholinergic side effects are frequent limitations. While these three drug classes have been the mainstay of pharmacologic treatment for decades, their use is largely supported by observational studies. None address the underlying molecular mechanisms of the disease.

Septal reduction therapy (SRT), either septal myectomy or alcohol septal ablation, is recommended for patients with symptomatic oHCM, who are refractory to medical treatment. Septal reduction therapy substantially improves symptoms and quality of life but may not be appropriate for patients with serious comorbidities or frailty and others who may prefer not to undergo an invasive procedure. To be effective and safe, these procedures require substantial operator experience, which is limited to a few centres of excellence and is not accessible to the majority of patients worldwide. Therefore, medical management of oHCM remains a major unmet need.

**Mavacamten**

Mavacamten is a selective, allosteric, reversible small molecular cardiac myosin inhibitor, which represents the first disease-specific treatment for oHCM targeting the core pathophysiologic mechanism of the disease (see Graphical Abstract, Supplementary data online, Prescribing Information). Preclinical studies have shown that mavacamten reduces the probability of myosin–actin cross-bridge formation by decreasing the number of myosin heads that can enter the ‘on actin’...
randomized, non–placebo-controlled, open-label, Phase 2 trial in 21 patients with symptomatic oHCM (Table 1). PIONEER-HCM was a 12-week, proof-of-concept and safety, non-placebo-controlled, open-label, Phase 2 trial in 21 patients with symptomatic oHCM (Table 1). Two cohorts of patients were studied. In Cohort A, patients were started on mavacamten at 10 or 15 mg/day, with dose titration at 4 weeks based on a targeted reduction in resting LV ejection fraction (LVEF) by 15%–20% from baseline. In Cohort B, patients were started on mavacamten at 2 mg/day, with the potential to increase to 5 mg/day at 4 weeks if the resting LVOT gradient had not decreased by >50% from baseline. Both cohorts met the primary endpoint of reduction of the post-exercise LVOT gradient from baseline to Week 12, with significant mean changes of −89.5 and −25.0 mmHg in Cohorts A and B, respectively. Administration of mavacamten also resulted in improvements in secondary endpoints, including resting and Valsalva gradients, left ventricular outflow tract gradients, exercise capacity [measured as peak oxygen consumption (pVO2)], ventilatory efficiency [volume expired/carbon dioxide production slope (Ve/VCO2 slope)], and numerical rating scale dyspnoea score.

Mavacamten reduced LVEF in a concentration-dependent manner, with substantial reductions in LVOT obstruction occurring at plasma concentrations between 350 and 695 ng/mL. In this range, all patients maintained an LVEF >50%. Plasma concentrations above 695 ng/mL were associated with reduction in LVEF to 34%–49%. Otherwise, mavacamten was generally well tolerated with most adverse events (AEs) considered mild or moderate and unrelated to the study drug.

**PIONEER open-label extension**

Patients who participated in PIONEER-HCM were invited to participate in an ongoing open-label extension study, PIONEER-OLE. After a washout period, the starting dose of mavacamten was 5 mg/day followed by titration at 6 weeks to doses of 5, 10, or 15 mg/day to achieve a plasma concentration of 250–500 ng/mL. An interim analysis after 48 weeks of treatment showed persistent and durable reductions in LVOT obstruction, in New York Heart Association (NYHA) functional class and serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). Patient-reported symptoms assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) also improved. Importantly, LVEF remained above 50% in all patients. An additional follow-up at 3 years was associated with sustained improvement in cardiovascular haemodynamics, symptoms, and quality of life.

---

**(power-generating) state and shifts the myosin population towards an energy-sparing, super-relaxed ‘off actin’ state** by reversibly binding to myosin ATPase (Figure 1). In vivo mouse models that express human myosin mutations and cause oHCM develop age-dependent LVH. Early treatment of these models with mavacamten prevents the development of LVH. Structural studies have shown that while HCM mutations disrupt normal interactions between sarcomere proteins, mavacamten normalizes these interactions and restores physiologic sarcomere function.

By normalizing the ratio of ‘on’ and ‘off’ myosin heads, mavacamten reduces sarcomeric hyperactivity and the resultant myocardial hypercontractility, reducing LVOT obstruction and reducing LV filling pressure. Mavacamten has also been shown to reduce maximal force, Ca2+ sensitivity, myocardial energy demands, and diastolic dysfunction. In a feline model of oHCM, mavacamten was shown to inhibit myosin ATPase and reduce outflow tract obstruction. Additional studies are needed to establish whether mavacamten has other disease-modifying potential of the structural abnormalities of oHCM.

Phase 1 trials of mavacamten were conducted to determine the pharmacokinetic properties and to assess its safety and tolerability. The drug is readily absorbed and is extensively metabolized, primarily through cytochrome (CYP) P450 enzymes, CYP2C19 as well as CYP3A4. The terminal half-life of mavacamten is dependent on CYP2C19 metabolic status and ranges from 6 to 23 days. Inducers and inhibitors of CYP2C19 and CYP3A4 may influence mavacamten systemic exposure.

### PIONEER-HCM

PIONEER-HCM was a 12-week, proof-of-concept and safety, non-randomized, non–placebo-controlled, open-label, Phase 2 trial in 21 patients with symptomatic oHCM (Table 1). Two cohorts of patients were studied. In Cohort A, patients were started on mavacamten at 10 or 15 mg/day, with dose titration at 4 weeks based on a targeted reduction in resting LV ejection fraction (LVEF) by 15%–20% from baseline. In Cohort B, patients were started on mavacamten at 2 mg/day, with the potential to increase to 5 mg/day at 4 weeks if the resting LVOT gradient had not decreased by >50% from baseline.

Both cohorts met the primary endpoint of reduction of the post-exercise LVOT gradient from baseline to Week 12, with significant mean changes of −89.5 and −25.0 mmHg in Cohorts A and B, respectively. Administration of mavacamten also resulted in improvements in secondary endpoints, including resting and Valsalva gradients, left ventricular outflow tract gradients, exercise capacity [measured as peak oxygen consumption (pVO2)], ventilatory efficiency [volume expired/carbon dioxide production slope (Ve/VCO2 slope)], and numerical rating scale dyspnoea score.

Mavacamten reduced LVEF in a concentration-dependent manner, with substantial reductions in LVOT obstruction occurring at plasma concentrations between 350 and 695 ng/mL. In this range, all patients maintained an LVEF >50%. Plasma concentrations above 695 ng/mL were associated with reduction in LVEF to 34%–49%. Otherwise, mavacamten was generally well tolerated with most adverse events (AEs) considered mild or moderate and unrelated to the study drug.

**Mavacamten** reduces sarcomeric hyperactivity and the resultant myocardial hypercontractility, reducing LVOT obstruction and reducing LV filling pressure. Mavacamten has also been shown to reduce maximal force, Ca2+ sensitivity, myocardial energy demands, and diastolic dysfunction. In a feline model of oHCM, mavacamten was shown to inhibit myosin ATPase and reduce outflow tract obstruction. Additional studies are needed to establish whether mavacamten has other disease-modifying potential of the structural abnormalities of oHCM.

Phase 1 trials of mavacamten were conducted to determine the pharmacokinetic properties and to assess its safety and tolerability. The drug is readily absorbed and is extensively metabolized, primarily through cytochrome (CYP) P450 enzymes, CYP2C19 as well as CYP3A4. The terminal half-life of mavacamten is dependent on CYP2C19 metabolic status and ranges from 6 to 23 days. Inducers and inhibitors of CYP2C19 and CYP3A4 may influence mavacamten systemic exposure.

### PIONEER-HCM

PIONEER-HCM was a 12-week, proof-of-concept and safety, non-randomized, non–placebo-controlled, open-label, Phase 2 trial in 21 patients with symptomatic oHCM (Table 1). Two cohorts of patients were studied. In Cohort A, patients were started on mavacamten at 10 or 15 mg/day, with dose titration at 4 weeks based on a targeted reduction in resting LV ejection fraction (LVEF) by 15%–20% from baseline. In Cohort B, patients were started on mavacamten at 2 mg/day, with the potential to increase to 5 mg/day at 4 weeks if the resting LVOT gradient had not decreased by >50% from baseline.

Both cohorts met the primary endpoint of reduction of the post-exercise LVOT gradient from baseline to Week 12, with significant mean changes of −89.5 and −25.0 mmHg in Cohorts A and B, respectively. Administration of mavacamten also resulted in improvements in secondary endpoints, including resting and Valsalva gradients, left ventricular outflow tract gradients, exercise capacity [measured as peak oxygen consumption (pVO2)], ventilatory efficiency [volume expired/carbon dioxide production slope (Ve/VCO2 slope)], and numerical rating scale dyspnoea score.

Mavacamten reduced LVEF in a concentration-dependent manner, with substantial reductions in LVOT obstruction occurring at plasma concentrations between 350 and 695 ng/mL. In this range, all patients maintained an LVEF >50%. Plasma concentrations above 695 ng/mL were associated with reduction in LVEF to 34%–49%. Otherwise, mavacamten was generally well tolerated with most adverse events (AEs) considered mild or moderate and unrelated to the study drug.

**PIONEER open-label extension**

Patients who participated in PIONEER-HCM were invited to participate in an ongoing open-label extension study, PIONEER-OLE. After a washout period, the starting dose of mavacamten was 5 mg/day followed by titration at 6 weeks to doses of 5, 10, or 15 mg/day to achieve a plasma concentration of 250–500 ng/mL. An interim analysis after 48 weeks of treatment showed persistent and durable reductions in LVOT obstruction, in New York Heart Association (NYHA) functional class and serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). Patient-reported symptoms assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) also improved. Importantly, LVEF remained above 50% in all patients. An additional follow-up at 3 years was associated with sustained improvement in cardiovascular haemodynamics, symptoms, and quality of life.

---

**Figure 1** Rationale for the use of mavacamten in hypertrophic cardiomyopathy. Molecular basis of hyper-contractility in hypertrophic cardiomyopathy and the effect of mavacamten. Hypertrophic cardiomyopathy-causing mutations may lead to a gain-of-function effect, increasing the proportion of myosin heads in the active state and leading to adverse energetic, structural, and clinical consequences. Mavacamten binds to the myosin molecules and reduces their likelihood of being in the active state, thus attenuating hyper-contractility and its adverse metabolic effects. Reprinted from Ho et al. (https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.120.006853) with permission from Wolters Kluwer Health, Inc.
In an analysis using artificial intelligence (AI)-enhanced electrocardiography (AI-ECG) to monitor disease status, mean HCM scores from two different AI-ECG algorithms decreased over time with mavacamten, suggesting improvement in ECG morphology. Artificial intelligence-enhanced electrocardiography scores also correlated with favourable measures of disease status, including reductions in Valsalva LVOT gradients and NT-proBNP levels.

**EXPLORER-HCM**

Based on the encouraging results of the PIONEER-HCM trial, mavacamten was advanced to EXPLORER-HCM, a pivotal Phase 3 trial, the largest, double-blind, placebo-controlled, randomized trial in oHCM with a myosin inhibitor conducted to date (Table 1, Figure 2, Supplementary data online, Prescribing Information and Table S2).36,45 The trial was carried out in 68 centres in 13 countries and randomized 251 patients with symptomatic (NYHA Class II/III) oHCM with an LVEF >55%. Almost all patients (92%) were on beta-blocker or calcium channel blocker therapy; treatment with disopyramide was not permitted due to concern over its additive negative inotropic effect in association with mavacamten. The mean age was 58.5 years, and the mean LVEF 74%. The LVOT gradients at rest had a mean of 51.5 mmHg and rose to 73 mmHg with Valsalva.

The starting dose of mavacamten was 5 mg/day with dose adjustments at Weeks 8 and 14 to achieve a Valsalva LVOT gradient <30 mmHg and a mavacamten plasma concentration of 350–700 ng/mL.36 There are a number of ways in which clinical outcomes in oHCM can be assessed. In EXPLORER-HCM, the primary endpoint was a composite of exercise capacity, symptom burden and continued eligibility for SRT. Among patients treated with mavacamten, improvements in pVO2 and the VE/VCO2 slope correlated significantly with reductions in NT-proBNP and hs-cTnI. Treatment with mavacamten also significantly improved non-peak exercise parameters, including V E/VCO2, circulatory power, exercise time, and end-tidal carbon dioxide (PETCO2). Treatment with mavacamten also significantly improved peak exercise parameters, including V VCO2 slope, ventilatory power, resting PETCO2, and O2 uptake/workload slope. Among patients treated with mavacamten, improvements in pVO2 and the VE/VCO2 slope correlated significantly with reductions in NT-proBNP (P = .002 and P = .003, respectively). No such correlations were observed in the placebo group.36,46 Thus, these findings demonstrate that mavacamten improved a broad range of both peak and sub-maximal cardiopulmonary exercise testing (CPET) parameters in patients with oHCM. Results were similar in pre-specified subgroups, including sex, age, duration of diagnosis, LV filling pressure, and presence or absence of hypertension.

**Safety**

Among the 251 patients in EXPLORER-HCM, 10 patients (8%) in the mavacamten group experienced 11 serious AEs (SAEs), while in the placebo group, 11 patients (9%) experienced 20 SAEs.36 Eight patients experienced cardiac SAEs, including four patients in the mavacamten group (two stress cardiomyopathy and two atrial fibrillation) and four patients in the placebo group (four atrial fibrillation, including...
one accompanied by heart failure). Temporary drug discontinuation due to LVEF <50% was reported in five patients (three in the mavacamten group and two in the placebo group). Four more patients (3.3%) on mavacamten had LVEF <50% at the end of treatment, three of whom returned to baseline values by the end of washout. Two patients in the mavacamten group permanently discontinued treatment due to AEs (atrial fibrillation, syncope), and one patient in the placebo group died suddenly.\(^45\)

**EXPLORER-HCM secondary analyses**

**Impact of beta-blocker therapy**

A pre-specified subgroup analysis of EXPLORER-HCM showed that mavacamten's effects on the primary composite endpoint of pVO\(_2\) and NYHA class were greater in patients who were not taking beta-blockers during the study compared with those who were \((\text{Table 2}).\(^{36,47}\) This is explained largely by the blunting of heart rate response to exercise in treated patients. However, the benefits of mavacamten on LVOT obstruction, NYHA class, ventilatory efficiency (V\(_{\text{E}}\)/V\(_{\text{CO}_2}\) slope), KCCQ-CSS, and NT-proBNP levels were not altered by beta-blockade. These findings indicate that patients with oHCM can potentially benefit from mavacamten treatment irrespective of concomitant beta-blockade.

**Cardiac remodelling**

Two imaging sub-studies were carried out in EXPLORER-HCM to determine the effect of mavacamten on cardiac structure and function. The cardiac magnetic resonance (CMR) sub-study included 35 patients, 17 of whom received mavacamten \((\text{Figure 4}).\(^{48}\) After 30 weeks, a reduction in LV mass index, the primary endpoint of this sub-study, occurred with mavacamten but not with placebo \((-17.4 \text{ vs. } -1.6 \text{ g/m}^2; \ P < .0001\). When compared with placebo, mavacamten also significantly reduced maximum LV wall thickness and left atrial volume index \((\text{LAVI})\) from baseline. Cardiac magnetic resonance repeated after 96 weeks of treatment showed persistent cardiac remodelling and normal contractile function.\(^{49}\)

The echocardiographic substudy \(^{37}\) \((\text{Figure 5})\) showed that among patients with SAM of the mitral valve at baseline, those assigned to mavacamten showed a significantly higher percentage with complete resolution of SAM than those assigned to placebo. In patients with mitral regurgitation \((\text{MR})\) at baseline, 9% in the mavacamten group vs. no patients in the placebo group exhibited complete resolution of MR at 30 weeks \((P < .001)\). Patients in the mavacamten group had significant associations between serum NT-proBNP level reduction and echocardiographic parameters such as the LAVI, LV thickness, the ratio between mitral inflow velocity and annular early diastolic velocity \((E/e')\), e', and LVOT gradients \((\text{rest, Valsalva, and post-exercise; Table 2, Figure 6})\).

Thus, significant reductions in LAVI, LV mass index, and LV wall thickness with mavacamten were observed in both the CMR and echocardiographic sub-studies. Taken together, these observations indicate that mavacamten improves cardiac structure and function in patients with oHCM.

**Health status and quality of life**

Patients treated with mavacamten showed greater improvement in overall health status as measured by the KCCQ-CSS, a pre-specified secondary outcome of the trial, which was validated in 196 patients in the EXPLORER-HCM trial.\(^{50}\) Patients treated with mavacamten also experienced greater improvements in the KCCQ Overall Summary Score \((\text{KCCQ-OSS})\), which combines scores from the total symptom, physical limitation, social limitation, and quality of life subscales.\(^{51}\) The mean increase from baseline to Week 30 in the KCCQ-OSS was 14.9 in the mavacamten group compared with 5.4 in the placebo group \((P < .0001)\). Similar benefits were observed with mavacamten compared with placebo across all sub-scales. After treatment ended, these benefits of mavacamten on KCCQ scores did not persist; the scores returned to baseline levels after the 8-week washout period.

A separate analysis assessed the effects of mavacamten on health-related quality of life using the EuroQol 5-dimension 5-level \((\text{EQ-5D-5L})\) index score and the EuroQoL visual analogue scale \((\text{EQ-VAS});\)\(^{52}\) At Week 30, patients randomized to mavacamten reported significantly greater improvements in both EQ-5D-5L and EQ-VAS scores compared with placebo. Taken together, these
Figure 3 Left ventricular outflow tract gradients at baseline and after 30 weeks of mavacamten. (A) Gradients at rest. (B) Valsalva gradient. (C) Post-exercise gradient. Adapted from Olivotto et al.\textsuperscript{36} with permission from Elsevier.
Almost 75% of patients exhibited a greater relief of obstruction. Mavacamten improved NYHA class, exercise performance, key aspects of health status, and reduced serum NT-proBNP and troponin I levels and was, overall, safe and well tolerated. It’s clear that mavacamten benefited patients with oHCM, the physiological benefits of mavacamten translate into improved health status and quality of life.

**Table 2  EXPLORER-HCM secondary analyses**

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Key results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blocker subgroup analysis</td>
<td>• Mavacamten’s effects on primary endpoint (pVO2 and NYHA class) were greater in patients not receiving background BB than receiving them.</td>
</tr>
<tr>
<td>EXPLORER-HCM: N = 231 (BB: n = 189; no BB: n = 62) EXPLORER-LTE (NCT03723655) N = 231 (BB: n = 175; no BB: n = 56)</td>
<td>• Less improvements in pVO2 with mavacamten vs. placebo in patients on BB.</td>
</tr>
<tr>
<td></td>
<td>• Mavacamten showed greater benefits vs. placebo in LVOT gradient reduction, NYHA class, and NT-proBNP levels, irrespective of BB use.</td>
</tr>
<tr>
<td></td>
<td>• Mavacamten benefits maintained in MAVA-LTE with or without BB.</td>
</tr>
<tr>
<td></td>
<td>• Mavacamten improvements in V̇E/V̇CO2 slope similar with and without BB.</td>
</tr>
<tr>
<td>CMR subgroup study&lt;sup&gt;48&lt;/sup&gt;</td>
<td>N = 35</td>
</tr>
<tr>
<td></td>
<td>• Reductions in LV mass index greater with mavacamten vs. placebo; P &lt; .0001)</td>
</tr>
<tr>
<td></td>
<td>• Change in LV mass index correlated positively with change in hs-cTnI</td>
</tr>
<tr>
<td>Echocardiographic parameters&lt;sup&gt;37&lt;/sup&gt;</td>
<td>N = 251</td>
</tr>
<tr>
<td></td>
<td>• Complete resolution of mitral valve SAM in 81% of patients on mavacamten vs. 34% on placebo (P &lt; .0001)</td>
</tr>
<tr>
<td></td>
<td>• Complete resolution of mitral regurgitation. Nine per cent in mavacamten vs. no patients on placebo (P &lt; .001)</td>
</tr>
<tr>
<td></td>
<td>• Mavacamten improved diastolic function vs. placebo, including septal Ee′, and lateral Ee′ and LAVI (all P &lt; .0001)</td>
</tr>
<tr>
<td></td>
<td>• Mavacamten significantly reduced LV wall mass and LV thickness index (consistent with CMR)</td>
</tr>
<tr>
<td>Health status analysis&lt;sup&gt;50,51&lt;/sup&gt;</td>
<td>n = 180&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>• Improvements in KCCQ greater with mavacamten than placebo; major benefits in symptoms, physical limitations, and QoL</td>
</tr>
<tr>
<td></td>
<td>• Improvements in KCCQ reversed after mavacamten was stopped</td>
</tr>
<tr>
<td></td>
<td>• Mavacamten improved EQ-5D index more than placebo</td>
</tr>
</tbody>
</table>

**MAVA-LTE: EXPLORER-LTE cohort**

While EXPLORER-HCM was under FDA review, the patients who completed the trial were invited to enrol in the EXPLORER-LTE cohort of MAVA-LTE, an ongoing, open-label, dose-blinded, long-term extension study (NCT03723655). Of the 244 patients who completed EXPLORER-HCM, 231 (95%) enrolled in EXPLORER-LTE. After washout of the original treatment (mavacamten or placebo), patients from both arms were started on mavacamten 5 mg/day, with dose adjustments at 4, 8, 12, and 24 weeks based on site-read echocardiographic measures of the Valsalva LVOT gradient and LVEF. This differed from the parent study in which dose adjustment was based on serum mavacamten concentration and central-read echocardiographic parameters. After 24 weeks, dose increases were permitted if the site-read Valsalva LVOT gradient was >30 mmHg or if the post-exercise gradient was >50 mmHg and the LVEF was ≥50%.

An interim analysis performed at a median follow-up of 62.3 weeks showed that mavacamten was associated with clinically important and sustained improvements of LVOT gradients, NYHA class, and NT-proBNP levels that were consistent with those observed in the parent trial. Treatment with mavacamten was generally well tolerated over 315 patient-years of exposure. Of the 231 patients in EXPLORER-LTE,
34 (15%) experienced SAEs at the time of data cut-off, including 5 patients (2.2%) with events related to the drug (3 heart failure and 2 decreased LVEF). Cardiovascular-related AEs that resulted in permanent treatment discontinuation included decreased LVEF (two patients), heart failure, cardiac arrest, and acute myocardial infarction (one patient each). Temporary treatment discontinuation was required in 26 (11%) patients, which included 12 (5.2%) who temporarily discontinued due to LVEF <50%. Left ventricular ejection fraction recovered to >50% in all of them. Seven of these participants resumed treatment, while five withdrew from the study.

These interim results from EXPLORER-LTE support the longer term use of mavacamten in patients with symptomatic oHCM as well as a dose titration and monitoring strategy guided exclusively by site-measured clinical parameters, including LVOT gradients and LVEF, as specified in the current prescribing information (see Supplementary data online, Prescribing Information).

**VALOR-HCM**

VALOR-HCM was a randomized, double-blind, placebo-controlled, Phase 3 trial that enrolled 112 patients (Table 1).

### Figure 4

Cine end-diastolic cardiac magnetic resonance images of a patient with obstructive hypertrophic cardiomyopathy: effects of mavacamten. Baseline before treatment (A and C) and after 30 weeks of mavacamten (B and D). Mid short axis (A and B). Four-chamber long axis (C and D). Compared with baseline, at Week 30, left ventricular mass and maximal wall thickness were reduced from 149 g/m² and 26 mm to 117 g/m² and 20 mm, respectively; maximal left atrial size fell from 77 to 59 mL/m². Left atrial total emptying fraction increased from 27% to 50%. Data are from the EXPLORER-HCM trial. Images courtesy of Dr Raymond Kwong, Brigham and Women’s Hospital.
who were on standard-of-care background therapies. Mavacamten not only reduced LVOT obstruction and enhanced left ventricular filling but also improved exercise capacity, quality of life, and symptom burden and provided global, multi-dimensional improvement in clinically relevant CPET, CMR, and echocardiographic parameters, patient-reported outcome measures, and biomarkers. Mavacamten also reduced the need for SRT after 16–32 weeks of treatment of severely symptomatic patients with oHCM on maximally tolerated medical therapy. Two of the trials (PIONEER-HCM and EXPLORER-HCM) used pharmacokinetic monitoring.

In 2022, at the time of FDA approval, Bristol Myers Squibb announced that the wholesale acquisition cost per capsule was ∼$245.20 with a monthly list price of $735.16.

Safety
Because mavacamten may cause decreases in LVEF, regular monitoring for clinical symptoms of heart failure (e.g. dyspnoea, fatigue, palpitations, worsening or new arrhythmia, leg oedema) and for systolic dysfunction is recommended, including echocardiographic assessments at 4, 8, and 12 weeks after initiating mavacamten treatment and every 12 weeks thereafter (see Supplementary data online, Prescribing Information). For patients with LVEF <50% at any time during mavacamten treatment, temporary or permanent treatment discontinuation is warranted (see Supplementary data online, Figure S1). Open-label, follow-up studies evaluating the long-term efficacy and safety of mavacamten in the three cited trials will provide more information on the durability of improvements and the safety profile of the drug.

To minimize risk, mavacamten is currently available in the USA through a Risk Evaluation and Mitigation Strategy (REMS) programme, designed to monitor patients periodically with echocardiograms for early detection of systolic dysfunction and to screen for drug interactions prior to each prescription fill. Risk Evaluation and Mitigation Strategy requires the healthcare provider and pharmacist to undergo educational programmes, including counselling patients on the risk of heart failure, assessing the patient’s cardiovascular status, and obtaining echocardiograms at specific times after starting the drug. It also provides a guide for patients who should be screened for potential drug–drug interactions and undergo an echocardiogram prior to enrolling in the REMS programme (see Supplementary data online, REMS).

In commenting on the safety findings of EXPLORER-HCM, the FDA review stated:

Although it is unclear whether the magnitude of improvement in pVO$_2$ in this trial (mean treatment effect for pVO$_2$ of 1.4 mL/kg/min) will lead to improved mortality, the consistency of effect between variables (i.e. improvement of pVO$_2$, reduction or no worsening of NYHA class, improvements in patient reported outcomes and reduction of the LVOT gradient), provided compelling evidence of the utility of mavacamten for improving how patients with oHCM feel and function.

In commenting on the safety findings of EXPLORER-HCM, the FDA review stated:

**Figure 5** Echocardiographic images of a patient with obstructive hypertrophic cardiomyopathy: effects of mavacamten. (A) At baseline, colour Doppler shows flow acceleration in the left ventricular outflow tract and significant mitral regurgitation. (B) At baseline, continuous wave Doppler through the left ventricular outflow tract shows a late peak consistent with dynamic left ventricular outflow tract obstruction and a peak gradient of 83 mmHg. (C) Continuous wave Doppler flow through the left ventricular outflow tract demonstrates an early peak and reduction of the peak gradient to 8 mmHg. (D) Following 30 weeks of mavacamten, the colour Doppler flow in the left ventricular outflow tract and in the mitral regurgitation jet are consistent with resolution of the left ventricular outflow tract obstruction and reduction in mitral regurgitation, respectively. Data are from the EXPLORER HCM trial. Images courtesy of Dr Sheila Hegde, Brigham and Women’s Hospital.
The overall safety profile of mavacamten was similar to placebo in the setting of careful safety monitoring. The main concern is mavacamten-mediated reversible induction of systolic dysfunction in the real-world setting where rigorous safety monitoring may not occur, thus potentially magnifying the differential risk of heart failure and/or systolic dysfunction observed in the Phase 3 trial.45

The precise role of myosin inhibition in the management of oHCM is not clear at this time. However, the National Institute for Health and Care Excellence in the UK recommends mavacamten 'as an option for treating obstructive hypertrophic cardiomyopathy in adults who have a NYHA class of II or III, if it is an add-on to individually optimized standard care that includes beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.53,54

It would appear that maintaining patients on the standard drugs should not be considered mandatory in order to proceed to mavacamten since important limiting side effects or contraindications to these agents may exist. The DISCOVER-HCM registry for mavacamten (NCT05489705) is expected to enrol ~1500 patients with oHCM and will assess the real-world safety and effectiveness of mavacamten in the USA. ClinicalTrials.gov lists trials on adult patients with oHCM in China (NCT05174416) and Japan (NCT05414175). The EMBARK-HFpEF trial (NCT04766892) will examine its role in heart failure with preserved ejection fraction and the ODYSSEY-HCM trial (NCT05582395) non-oHCM. As the results from these trials become available, it will be possible to develop more precise clinical guidelines for the role of mavacamten.

The future

More information is needed to understand the characteristics and predictors of responders vs. non-responders, the safety and efficacy of mavacamten begun in childhood, the responses in different genotypes, and the role of mavacamten in non-oHCM; a pilot study of the latter has been performed,55 and a Phase 3 ODYSSEY trial of such patients has begun (NCT05582395).56 It is not known whether patients with heart failure and preserved ejection fraction without HCM can be improved by mavacamten; a proof of concept trial to test this is ongoing in the EMBARK HFpEF trial (NCT04766892).60 More follow-up is also needed to determine whether mavacamten can reduce the need for SRT in the longer term. Optimal duration of therapy and the potential disease-modifying effects of mavacamten in HCM should be defined.

Aficamten, a synthesized next-generation, small-molecular, selective cardiac myosin inhibitor, has a shorter human half-life (3.4 days) than mavacamten (7–9 days), allowing a shorter time interval to reach a steady state plasma concentration and more rapid reversibility after dose reduction.61 In a feline translational model of oHCM, aficamten demonstrated a dose-dependent reduction of the LVOT pressure gradients.62 A Phase 1 dose escalation study in normal subjects showed aficamten to be well tolerated and to reduce LVEF in a concentration dependent manner.63

In REDWOOD-HCM (NCT 04212896), a Phase 2, placebo-controlled trial of 41 patients with oHCM with peak LVOT gradients >50 mmHg and LVEF >60%, aficamten appeared to be safe, well tolerated, and reduced the systolic pressure gradient at rest and after Valsalva; it also reduced both LVEF and symptoms.64 In FOREST-HCM (NCT04848508), the open-label extension of the REDWOOD-HCM trial, aficamten maintained efficacy and was well tolerated for up to 48 weeks. Of the 19 patients meeting standard criteria for SRT at baseline, none still met these criteria at 48 weeks.55 The Phase 3 SEQUOIA-HCM study (NCT05186818) is currently ongoing.66 ClinicalTrials.gov also lists two other aficamten trials, MAPLE-HCM (NCT05767346) comparing it with metoprolol and FOREST HCM (NCT04848506), an open-label study to collect safety data.
Conclusions

Mavacamten is the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic oHCM. It provides a novel pharmacologic treatment option for patients, which targets the underlying pathophysiology of the disease, and it is well tolerated in a large majority of patients. Results from ongoing long-term extension studies and real-world experience in clinical practice will expand upon the efficacy and safety findings obtained in the clinical trials summarized in this review.

Based on the available data, mavacamten is beneficial, at least in the short to medium term, in patients with oHCM who remain symptomatic despite single or multi-drug dose treatment with beta-blockers and calcium channel blockers and may postpone or avoid the need for SRT.

Supplementary data

Supplementary data are available at European Journal of Heart online.

Declarations

Disclosure of Interest

E.B. has received research support through Brigham and Women’s Hospital from AstraZeneca, Daiichi-Sankyo, Merck, and Novartis and payments as a consultant from MyoKardia Inc., a wholly owned subsidiary of Bristol Myers Squibb and from Amgen, Boehringer-Ingelheim/ Lilly, Cardurion, NovoNordisk, and Verve. S.S. has received personal fees from MyoKardia Inc., a wholly owned subsidiary of Bristol Myers Squibb and payments as a consultant for Cytokinetics. T.P.A. has no compensation for the preparation of this review. Writing and editorial support were provided by Kim Fuller, Medical Writing and Editorial Services, funded by MyoKardia Inc., a wholly owned subsidiary of Bristol Myers Squibb. The authors received no compensation for the preparation of this review.

References
